Immunoclin Corp: 10-Q filed 2014-07-24
What Immunoclin Corp reported in its quarterly report filed 2014-07-24 (fiscal Q1 2014): 30 published measures, 57 facts as tagged in accession 0001517126-14-000229.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2014-07-24
- Fiscal period
- fiscal Q1 2014
- Accession
- 0001517126-14-000229 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Immunoclin Corp filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-04-30 | 20,209,329 | USD | |
| At 2014-01-31 | 20,528,709 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-04-30 | 19,055,030 | USD | |
| At 2014-01-31 | 19,803,241 | USD | |
| At 2013-01-31 | -310,388 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-02-01 to 2014-04-30 | -793,559 | USD | 89 |
| 2013-02-01 to 2014-01-31 | -12,980,317 | USD | 365 |
| 2013-02-01 to 2013-04-30 | -43,877 | USD | 89 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-02-01 to 2014-04-30 | -102,582 | USD | 89 |
| 2013-02-01 to 2013-04-30 | -27,603 | USD | 89 |
Capital expenditure payments
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-02-01 to 2014-04-30 | 4,457 | USD | 89 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-02-01 to 2014-04-30 | 145,118 | USD | 89 |
| 2013-02-01 to 2013-04-30 | 21,034 | USD | 89 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-02-01 to 2014-04-30 | -4,457 | USD | 89 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-04-30 | -13,656,328 | USD | |
| At 2014-01-31 | -12,862,769 | USD |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-04-30 | 10,048 | USD | |
| At 2014-01-31 | 6,241 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-02-01 to 2014-04-30 | 249,332 | USD | 89 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-02-01 to 2014-04-30 | -795,865 | USD | 89 |
| 2013-02-01 to 2013-04-30 | -44,550 | USD | 89 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-04-30 | 135,438 | USD | |
| At 2014-01-31 | 74,010 | USD |
Interest expense
Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-02-01 to 2013-04-30 | 5 | USD | 89 |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-04-30 | 1,154,299 | USD | |
| At 2014-01-31 | 725,468 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-04-30 | 174,607 | USD | |
| At 2014-01-31 | 177,817 | USD |
Goodwill carrying amount
Recognized goodwill remaining after accumulated impairment. It arises from business combinations and does not measure the current value of the company’s brand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-04-30 | 654,992 | USD | |
| At 2014-01-31 | 654,992 | USD |
Net finite-lived intangible assets
Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-04-30 | 19,408,851 | USD | |
| At 2014-01-31 | 19,793,466 | USD |
Net current accounts receivable
Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-04-30 | 22,658 | USD | |
| At 2014-01-31 | 14,309 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-02-01 to 2014-04-30 | 795,865 | USD | 89 |
| 2013-02-01 to 2013-04-30 | 44,550 | USD | 89 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-02-01 to 2014-04-30 | 7,959 | USD | 89 |
| 2013-02-01 to 2013-04-30 | 5,101 | USD | 89 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-04-30 | 26,421,154 | shares | |
| At 2014-01-31 | 26,503,515 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-04-30 | 33,206,856 | USD | |
| At 2014-01-31 | 33,164,274 | USD |
Comprehensive income or loss
Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-02-01 to 2014-04-30 | -805,921 | USD | 89 |
| 2013-02-01 to 2013-04-30 | -39,753 | USD | 89 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-02-01 to 2014-04-30 | 80,544 | USD | 89 |
| 2013-02-01 to 2013-04-30 | 35,875 | USD | 89 |
Depreciation expense
Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-02-01 to 2014-04-30 | 650 | USD | 89 |
| 2013-02-01 to 2013-04-30 | 364 | USD | 89 |
Depreciation, depletion and amortization
Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-02-01 to 2014-04-30 | 650 | USD | 89 |
| 2013-02-01 to 2013-04-30 | 364 | USD | 89 |
Amortization of intangible assets
Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-02-01 to 2014-04-30 | 384,615 | USD | 89 |
Nonoperating income or expense
Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-02-01 to 2014-04-30 | 2,306 | USD | 89 |
| 2013-02-01 to 2013-04-30 | 673 | USD | 89 |
Change in accounts receivable
The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-02-01 to 2014-04-30 | 8,349 | USD | 89 |
| 2013-02-01 to 2013-04-30 | -20,285 | USD | 89 |
Change in accounts payable
The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-02-01 to 2014-04-30 | 16,790 | USD | 89 |
| 2013-02-01 to 2013-04-30 | -2,322 | USD | 89 |
Inspect the source
- Entity
- Immunoclin Corp / CIK 0001520047
- Captured
- SEC response SHA-256
cdfbf3ddd493bed046dd28be8c53e20201b60478d7022019645c6ed835ac7b05
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001520047.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))